In this study, the benzimidazole derivatives were synthesized and evaluated as imaging agents for the NR2B subype of NMDA receptor. Among these ligands, Although the brain uptake of these benzimidazole derivatives was too low to allow for in vivo SPECT imaging, these compounds might be useful scaffolds for the development of imaging probes specific for the NMDA receptors.
Introduction
The N-methyl-D-aspartate (NMDA) receptor, a member of the glutamate receptors, plays an important role in the neurotransmission function of the central nervous system (CNS). 1 Overactivation of the NMDA receptor, however, is thought to cause various disorders, such as ischemia, stroke, Parkinson's Disease, Alzheimer's Disease, Huntington's Disease, and schizophrenia. [2] [3] [4] [5] [6] NMDA receptors are heteromers, which contain an NR1 subunit and one or more types of the different NR2 subunits (NR2A-D). 7 NR1 subunit has only one gene (8 splice variants) with ubiquitous distribution in the brain. NR2 subunits, on the other hand, exhibit distinct distribution in the brain, which determine the synaptic localization and function of the NMDA receptor.
The NR2A subunit is widely distributed throughout the brain; but, the NR2B subunit is confined in the forebrain region, including the cerebral cortex, hippocampus, and olfactory bulb. The NR2C and NR2D are localized in the cerebellum and diencephalus/lower brain stem, respectively. The NR2A and NR2B are known to be the predominant NR2 subunits in the adult forebrain. 8 It is suggested that NR2A-containing NMDA receptors are involved in prosurvival signaling; thereby, they exert a neuroprotective action against glutamate receptor-dependent apoptotic neuronal injuries. [9] [10] [11] On the other hand, an increasing number of reports have demonstrated the importance of the NR2B subunit in determining the pharmacological and functional properties of the NMDA receptor. The NR2B has been implicated in modulating functions, such as learning, memory processing, and feeding behaviors, as well as being involved in a number of human disorders. 12 It is suggested that activation of the NR2B-containing NMDA receptor initiates apoptotic signaling cascades and promotes neuronal death. [9] [10] [11] Recent progress in molecular biology revealed the in vitro function of the NR2B-containing NMDA receptor considerably. However, its function in the living brain is not well understood due to the lack of visualizing method in vivo.
positron emission tomography (PET) and single photon emission computed tomography (SPECT) are the most efficient imaging methods for in vivo measurement of neurotransmitter receptors and enzymes in the brain. Our study, as well as other studies, have developed several radioligands for the NR2B subunit of the NMDA receptor ( Fig. 1) . These ligands showed similar accumulation pattern with the localization of expression of the NR2B subunit only under in vitro condition but not in vivo. [13] [14] [15] [16] [17] [18] [19] Among these ligands, only [ 11 C]EMD-95885 showed significant reduction of the in vivo brain uptake by treatment with the NR2B ligand. 16 Although the inhibition pattern was inconsistent with NR2B expression, this chemical structure might be a useful lead for the development of potential imaging probes. Recently, a new series of benzimidazole derivatives 1 and 2 are developed as novel NR2B antagonists (Fig. 2) , 20 which have similar chemical structures with EMD-95885. For example, compound 1a showed excellent affinity for the NR2B subunit (Ki= 1.5 nM). Introduction of a hydrophobic substituent into the R 2 -position of benzimidazoles, such as compound 1, maintained receptor affinity. [20] [21] [22] On the bases, we designed new SPECT imaging agents, which introduced 125 I atom into the R 2 -position of benzimidazoles. In this study, [ 125 
I]
labeled benzimidazole derivatives were synthesized and the in vitro binding properties and in vivo brain uptake characteristics in rodents were examined. It is reported that 11 C labeled 4-acetoxy derivative of L-703,717, which is a PET ligand for glycine site of NMDA receptor, can be a substrate of P-gp 23 . However it is not clear if the NR2B ligands are substrates of P-gp. Some of NR2B ligands such as ifenprodil and benzidazoles in this series have acidic phenol group. It has been shown that organic anion transporter is responsible for the elimination of several acidic drugs from the brain across the BBB 24 . Therefore the effect of P-gp and OAT on the in vivo uptake of 
Results and discussion

Chemistry
Based on the previous structure-activity relationship studies, [20] [21] [22] the SPECT imaging agent candidates 8, 9, and 13 were designed, in which an iodine atom was introduced into the 4'-position (R 2 -position) of benzyl-or phenoxy-piperidine group of benzimidazoles. Lead compound 1a was synthesized according to the literature. 20 The 4'-Iodo substituted benzylpiperidine derivatives (8 and 9) were synthesized as shown in Scheme 1. Alkylation of compound 3 25 with ethyl bromoacetate gave 4 (71 % yield),
followed by a bromo-to-tributyltin exchange reaction gave tributyltin derivative 5 for yields of 53 %. Compound 5 was allowed to react with iodine in CCl 4 to give the iodo derivative 6 (68 % yield). Compound 6 was hydrolyzed, followed by general amide coupling reaction with the corresponding phenylenediamines. Dehydration of the amidated products in acetic acid at reflux gave the benzimidazoles 7 and 9 for yields of 55 % and 53 %, respectively. Compound 7 was converted to 8 by desmethylation with HBr (63 % yield). The target iodo phenoxypiperidine derivative (13) affinities were shown between benzimidazole-carboxamide derivatives substituted with methylene group and oxygen atom in X-position. 22 Therefore, it might be difficult to fit the binding space for phenoxypiperidine derivatives in the NR2B antagonist binding site. Since 8 and 9 had high affinity for the NR2B subunit of the NMDA receptor, these ligands were selected to carry out further biological evaluations on the corresponding I-125-labeled probes.
Radiochemistry
Trimethyltin precursors 14 and 15 were synthesized from 8 and 9, respectively, by an iodo-to-trimethyltin exchange reaction (53 % yield for 14 and 97 % yield for 15). 
In vitro autoradiography
In vitro regional distributions of [ 125 I]benzimidazoles on the rat brain sections were evaluated by a method mentioned in the literature. 13 As shown in the autoradiogram in Figure 3, showed high accumulation in the forebrain region (cerebral cortex, hippocampus), which is an NR2B-rich region, and lower uptake in the cerebellum, which is an NR2B-poor region (Fig. 3A and B) . These distribution patterns were similar to [ Figure 3C and D and quantified in Figure   3E and F, respectively. Almost no specific binding of both ligands exists in the cerebellum. The specific binding of [ values of 8 and 9 were 3.95 and 3.54, respectively as shown in Table 1 benzimidazoles as SPECT imaging agents for the NR2B-subunit-containing NMDA receptor.
In vivo pharmacology
The biodistribution studies of [ Table 3 , regional brain distribution at 180 min after the radiotracer injection was determined. As shown in figure 5 , pre-injection of non-radioactive 8 resulted in a significantly increased blood radioactivity of [ 125 I]8 (P < 0.01) compared with the control group. Altogether, the liver uptake was significantly decreased (P < 0.01). On the other hand, the brain uptake was increased slightly. Pre-administration of the NR2B selective antagonist, Ro-25,6981, had no effect on blood radioactivity of [ On the other hand, the brain uptake of commonly used PET radioligands, such as were not reported, however, calculated by ChemDraw Ultra to be 3.36 and 3.40, respectively. These ligands are not within the optimal range (1.0-3.0) for compounds expected to penetrate the BBB. 35 Therefore log P value might be one of the reasons that the ligands showed low brain uptake. Another reason was thought to be high uptake of NR2B ligands in lung. The basic piperidine group in the ligands might cause these accumulation proclivities. Alternatively, lower molecular weight derivatives might be necessary to increase BBB permeability.
Another likely reason for the low uptake could be the excretion from brain tissue by the efflux systems of the BBB. It has been shown that many radioligands for mapping neuroreceptors are substrates for P-gp. [36] [37] [38] It is reported that several acidic drugs are eliminated by the OAT from the brain across the BBB. 24 Since the phenolic group in 8 has acidic moiety, there is a possibility that the brain uptake of [ Table 4 , pretreatment with CsA resulted in the reduction of blood radioactivity level of [ 125 I]8 but increase in the brain uptake in the CsA group compared with the control group. Therefore, the brain to blood ratio was 1.6-fold higher than the control group. Although P-gp is known to be present in the liver and kidney, (Table 5 ). It is reported that probenecid is the substrate of OAT1 and 3. OAT1 is mainly expressed in the kidney and OAT3 in the kidney and brain. OATs play a role in the renal influx of probenecid. 40, 41 Therefore, this study indicated that [ Similar to this study, previously reported imaging agents for NR2B subunit of NMDA receptor showed consistent accumulation pattern with the expression of NR2B subunit and high specificity to NR2B rich region only under in vitro condition but not in vivo. [13] [14] [15] [16] [17] [18] [19] Moreover, similar binding characters were observed in the radioligands for other binding sites of NMDA receptor, such as ion-channel site 43, 44 and glycine site [45] [46] [47] . Kew et. al. suggested that ifenprodil might exhibit higher affinity for the agonist-bound activated and desensitized states of the NMDA receptor, respectively, relative to the resting, agonist-unbound state. antagonists were much more potent as a neuroprotectant at pH 6.5 than at pH 7.5. 48 The pH of ischemic tissue is as low as 6.5.
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In like manner, it is reported that 
Conclusion
Our study has developed high-affinity benzimidazole derivatives 8 and 
Ethyl 2-{4-(4-bromobenzyl)piperidin-1-yl} acetate (4)
To a solution of 3
23
(13.0 g, 51.15 mmol) in DMF (8.0 ml), diisopropylethylamine (10.65 ml, 61.26 mmol) and ethyl bromoacetate (6.84 ml, 61.26 mmol) were added, and the reaction mixture was stirred at room temperature for 3 h. EtOAc (50 ml) was added to the mixture, and the organic layers were washed with aqueous NaHCO 3 and brine, dried with Na 2 SO 4 , and evaporated to dryness. The crude product was chromatographed on silica gel with hexane/EtOAc = 2:1 to provide 4 (12.4 g, 
Ethyl 2-{4-(4-tributylstannylbenzyl)piperidin-1-yl} acetate (5)
To a solution of 4 (5.0 g, 14.69 mmol) in toluene (50 ml), bistributyltin (14.7 ml, 29.38 mmol) and tetrakis (triphenylphosphine) palladium (509 mg, 0.44 mmol) were added, and the reaction mixture was refluxed for 36 h. After cooling, the reaction mixture was filtered through celite. The filtrate was evaporated to dryness. The crude product was chromatographed on silica gel with hexane/EtOAc = 3:1 to provide 5 (4.30 g, 7.75 mmol, 53 %) as a colorless oil, 
Ethyl 2-{4-(4-iodobenzyl)piperidin-1-yl} acetate (6)
To a stirred solution of 5 (2.85 g, 5.17 mmol) in carbon tetrachloride (135 mL), 50 mM solution of iodine in dry carbon tetrachloride (135 mL, 6.72 mmol) was added dropwise, and the reaction mixture was allowed to stand at room temperature for 1 h.
The mixture was evaporated to dryness. The crude product was chromatographed on silica gel with hexane/EtOAc = 1:1 to provide 6 (1.36 g, 3.51 mmol, 68 %) as a colorless oil, 
2-{[4-(4-Iodobenzyl)piperidin-1-yl]methyl}-5-methoxybenzimidazole (7)
Compound 6 (804 mg, 2.08 mmol) was dissolved in 6 M HCl (5 ml), and the mixture was heated to 100 °C for 1 h. The reaction mixture was cooled and evaporated to dryness. The residue was dissolved in DMF (6 ml), followed by EDC (518 mg, 2.70 mmol), 1-hydroxy-7-azabenzotriazole (367 mg, 2.70 mmol), triethylamine (570 μl, 4.16 mmol), and 4-methoxy-1,2-phenylenediamine (287 mg, 2.08 mmol). The reaction mixture was stirred at room temperature for 3 h followed by quenching with aqueous NaHCO 3 and ethyl acetate. Organic layer was separated and washed by brine, dried with Na 2 SO 4 , and evaporated to dryness. The crude oil was dissolved in acetic acid (6 ml) and heated to 140 °C for 4 h. The reaction mixture was cooled and evaporated to dryness. The crude product was chromatographed on silica gel with CHCl 3 /MeOH = 20: 
2-{[4-(4-Iodobenzyl)piperidin-1-yl]methyl}benzimidazol-5-ol (8)
Compound 7 (530 mg, 1.15 mmol) was dissolved in HBr/H 2 O (48 %, 10 ml), and the mixture was heated to 100 °C for 6 h. The reaction mixture was cooled and evaporated to dryness. The crude product was chromatographed on silica gel with 
N-{2-[4-(4-Iodobenzyl)-piperidin-1-ylmethyl]benzoimidazol-5-yl}-
methanesulfonamide (9)
Using the above procedure for 7 with N- (3,4-diaminophenyl) 
Ethyl 2-{4-(4-Iodophenoxy)piperidin-1-yl} acetate (11)
Compound 10 (686 mg, 1.70 mmol) 25 was dissolved in 30 % TFA/CH 2 Cl 2 (5 ml), and the mixture was stirred at room temperature for 5 h followed by evaporated to dryness. The crude product was converted to the title compound 11 using the above procedure for compound 4. In result, compound 11 (300 mg, 45 
2-{[4-(4-Iodophenoxy)piperidin-1-yl]methyl}-5-methoxybenzimidazole (12)
Using the above procedure for 7 starting from compound 11, the title compound 
2-{[4-(4-Iodophenoxy)piperidin-1-yl]methyl}benzimidazol-5-ol (13)
Using the above procedure for 8 starting from compound 12, the title compound 
4.1.9.2-{[4-(4-Trimethylstannylbenzyl)piperidin-1-yl]methyl}benzimidazol-5-ol (14)
To a solution of 8 (50 mg, 0.125 mmol) in toluene (3 ml), bistrimethyltin (104 μl, 0.502 mmol) and tetrakis (triphenylphosphine) palladium (15 mg, 0.013 mmol) were added, and the reaction mixture was refluxed for 6 h. After cooling, the reaction mixture was filtered through celite. The filtrate was evaporated to dryness. The crude product was chromatographed on silica gel with CHCl 3 /MeOH = 15:1 to provide 14 (32 mg, 0.066 mmol, 53 %) as a colorless oil, 
4.1.10.
N-{2-[4-(4-Trimethylstannylbenzyl)-piperidin-1-ylmethyl]benzoimidazol-
5-yl}-methanesulfonamide (15)
Using the above procedure for 14 starting from compound 9, the title compound 
Radiosynthesis
In vitro binding assays
The Ki values of benzimidazoles for binding of [ displacing drug added to make a final volume of 500 μl for 120 min at 25 °C. In each experiment the assay buffer contained 100 mM trifluoroperazine. Non-specific binding was defined by the addition of unlabeled ifenprodil at 1 mM. Bound ligands were collected by rapid filtration using a Brandel cell harvester onto glass fiber filter (GF/B).
The filters were washed rapidly three times with 2.5 ml of ice-cold assay buffer.
Following separation and rinsed, the filters were placed into scintillation liquid (4 ml; ASCII, GE Healthcare Bio-Sciences) and radioactivity was determined with a liquid scintillation counter.
In vitro receptor autoradiography
The brain sagittal sections, obtained by the method described in the literature, 13 were pre-incubated for 30 min at 25 °C in 50 mM Tris-HCl buffer (pH 7.4 at 25 °C) containing 5% bovine serum albumin (BSA). These were subsequently incubated in the same buffer containing [ 
In vivo experiments
The [ 
Partition coefficient determination
Partition coefficient between n-octanol and buffer was measured by a conventional shake flask method in triplicate. The benzimidazoles (1-2 mg) were well shaken in a mixture of n-octanol (1 ml) and 10 mM phosphate buffer (pH 7.4, 1 ml) for 15 min at ambient temperature. After centrifugation (2500 rpm for 5 min) of the mixture, the two layers were separated and analyzed by HPLC (column; Nacalai Cosmosil (Table 1 ).
Data analysis
Data were expressed as the mean ± standard deviation. In vitro experiments of Table 4 . A value of P < 0.05 was considered statistically significant. The Ki values were obtained by the method in Ref. 25 . Each value (mean ± SD) was determined triplicate using rat cortical membrane homogenates in HEPES-KOH buffer. The partition coefficient between n-octanol and sodium phosphate buffer at pH=7.4 (log D 7.4 ) was determined by conventional shake-flask method (n = 3). 
